Table 1.
Clinicopathological characteristics of 52 patients
| Variables | eIF6—low (N, %) | eIF6—high (N, %) | p |
|---|---|---|---|
| Total | 35(67.3%) | 17 (32.7%) | |
| Clinical parameters | |||
| Gender | 1.000 | ||
| Male | 28 (53.8%) | 14 (26.9%) | |
| Female | 7 (13.5%) | 3 (5.8%) | |
| Age ( years) | 0.854 | ||
| < 60 | 21 (40.4%) | 9 (17.3%) | |
| ≥ 60 | 14 (26.9%) | 8 (15.4%) | |
| Differential | 0.662 | ||
| Poorly | 14 (26.9%) | 5 (9.6%) | |
| High/Moderately | 21 (40.4%) | 12 (23.1%) | |
| Lymph node metastasis | 1.000 | ||
| Negative | 20 (38.5%) | 9 (17.3%) | |
| Positive | 15 (28.8%) | 8 (15.4%) | |
| p Stage | 0.098 | ||
| 1 | 12 (23.1%) | 1 (1.9%) | |
| 2 | 5 (9.6%) | 4 (7.7%) | |
| 3 | 18 (34.6%) | 12 (23.1%) | |
| PET metabolic parameters | (median) | ||
| SUVmax | 0.010* | ||
| Low | 21 (40.4%) | 3 (5.8%) | |
| High | 14 (26.9%) | 14 (26.9%) | |
| SUVmean | 0.018* | ||
| Low | 22 (42.3%) | 4 (7.7%) | |
| High | 13 (25%) | 13 (25%) | |
| TLG | 0.237 | ||
| Low | 20 (38.5%) | 6 (11.5%) | |
| High | 15 (28.8%) | 11 (21.2%) | |
| MTV | 1.000 | ||
| Low | 18 (34.6%) | 8 (15.4%) | |
| High | 17 (32.7%) | 9 (17.3%) | |